Revolutionary Research from the Lab to the Bedside
A crucial part of our mission at University Hospitals is to make significant scientific discoveries about blood disorders and cancers and integrate them into our patients’ care. Our research scientists collaborate with clinicians at the point of care. Together, we find new therapies, drugs and medical devices that will change the way cancer and blood disorders are treated and bring them rapidly to our patients, including:
- Benefits of physical connection of proton therapy center to children’s hospital
- Collaborative drug development and testing for pediatric patients
- Distinct dosimetric advantages of proton therapy for pediatric cancer
- First-of-its-kind study documents gender differences in cancer treatment toxicity in children
- Improving cancer outcomes for adolescents and young adults
- Magnetic resonance fingerprinting (MRF)
- Moonshot’s Blue-Ribbon Panel Working Group on Cancer Immunology and Prevention
- Most up-to-date U.S. statistics for childhood brain tumors and CNS tumors
- National clinical study of a novel form of immunotherapy that is poised to change the standard of care for pediatric high-risk neuroblastoma patients
- Regulation of regulate normal immune cell function
- Stem cell transplant for rare diseases
Partnerships with Nationally Recognized Research Institutions
University Hospitals Rainbow Babies & Children’s partners with the prestigious Case Comprehensive Cancer Center (CCC), part of Case Western Reserve University School of Medicine. Case CCC is designated by the National Cancer Institute as a comprehensive cancer center – one of only 49 in the U.S. to earn this distinction. We are the primary pediatric affiliate of Case CCC. Through this relationship, we are linked with other medical institutions in a stronger and more unified effort to understand the causes and progression of cancer. We use this understanding to develop new treatments for infants, children, adolescents and young adults with cancer and improve patient outcomes.
Our pediatric cancer and blood disorder team also works closely with University Hospitals’ own Harrington Discovery Institute. This is an international initiative dedicated to physician-scientists. Our scholars strive to transform breakthrough discoveries into new medicines.
Additional national partnerships and affiliations include:
Access to More Clinical Trials and Innovative Therapies
Because of the strength in our research enterprise, our patients have access to new and promising treatment options. We are one of few sites in the world to offer the groundbreaking CAR T-cell therapy to children and young adults with relapsed or refractory (resistant cancer). This highly advanced therapy modifies a patient’s own immune cells, so they can identify and fight deadly cancer cells.
To keep our patients at the forefront of blood disorder treatment, our board-certified specialists participate in ongoing national and international research projects. Thanks to the latest medical advances, we’ve been able to diminish complication rates and reduce the number of hospital admissions for patients with sickle cell disease.
Our collaborative and multi-disciplinary approach makes clinical trials more accessible to pediatric patients. By working closely with the UH Seidman Cancer Center for adults, we are able to offer adolescent and young adult patients access to the same clinical trials that are typically only available for older patients.
As an academic medical center, at University Hospitals, we are steadfast in our commitment to advance medical treatment and improve outcomes for patients of all ages who are diagnosed with cancer or blood disorders.
Watch as Dr. John Letterio talks about chemoprevention.